BR112012023826A2 - composto para uso no tratamento de doenças baseadas na expressão de transcritos tóxicos. - Google Patents

composto para uso no tratamento de doenças baseadas na expressão de transcritos tóxicos.

Info

Publication number
BR112012023826A2
BR112012023826A2 BR112012023826A BR112012023826A BR112012023826A2 BR 112012023826 A2 BR112012023826 A2 BR 112012023826A2 BR 112012023826 A BR112012023826 A BR 112012023826A BR 112012023826 A BR112012023826 A BR 112012023826A BR 112012023826 A2 BR112012023826 A2 BR 112012023826A2
Authority
BR
Brazil
Prior art keywords
treatment
expression
compound
diseases based
transcripts
Prior art date
Application number
BR112012023826A
Other languages
English (en)
Inventor
Amparo Garcia López
Enrique Pérez Payá
Manuel Pérez Alonso
María Beatriz Llamusí Troisi
María Del Mar Orzáes Calatayud
Ruben Darío Artero Allepuz
Original Assignee
Consejo Superior Investigacion
Fundacióm De La Comunidad Valenciana Ct De Investigacion Principe Felipe
Uni De Valéncia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Fundacióm De La Comunidad Valenciana Ct De Investigacion Principe Felipe, Uni De Valéncia filed Critical Consejo Superior Investigacion
Publication of BR112012023826A2 publication Critical patent/BR112012023826A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composto para uso no tratamento de doenças baseadas na expressão de transcritos tóxicos. a invenção se refere a compostos para serem usados no tratamento de doenças com base na expressão dos transcritos tóxicos. a presente invenção refere-se a moléculas peptídicas, especificamente hexapeptídeos, para a prevenção e/ou tratamento de doenças cuja etiologia se baseia na presença de transcritos tóxicos que compreenem repetiçoes cug, ccug, cgg, cag e aag, de preferênci : dm1, sca8, dm2, fxtas, hd e fa.
BR112012023826A 2010-03-26 2011-03-09 composto para uso no tratamento de doenças baseadas na expressão de transcritos tóxicos. BR112012023826A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201030462A ES2365967B1 (es) 2010-03-26 2010-03-26 Compuestos para ser usados en el tratamiento de enfermedades basadas en la expresión de transcritos tóxicos con repeticiones cug o ccug.
PCT/ES2011/070159 WO2011117448A1 (es) 2010-03-26 2011-03-09 Compuestos para ser usados en el tratamiento de enfermedades basadas en la expresión de transcritos tóxicos

Publications (1)

Publication Number Publication Date
BR112012023826A2 true BR112012023826A2 (pt) 2016-11-29

Family

ID=44672480

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023826A BR112012023826A2 (pt) 2010-03-26 2011-03-09 composto para uso no tratamento de doenças baseadas na expressão de transcritos tóxicos.

Country Status (10)

Country Link
US (1) US20130143825A1 (pt)
EP (1) EP2554180A4 (pt)
JP (1) JP2013523624A (pt)
CN (1) CN102933224A (pt)
BR (1) BR112012023826A2 (pt)
CA (1) CA2800248A1 (pt)
ES (1) ES2365967B1 (pt)
MX (1) MX2012010888A (pt)
RU (1) RU2012145458A (pt)
WO (1) WO2011117448A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3020404A1 (en) 2014-11-14 2016-05-18 Universitat de Valéncia Caffeine for the treatment of myotonic dystrophy type 1 and type 2
EP3020403A1 (en) 2014-11-14 2016-05-18 Universitat de Valéncia Compounds for the treatment of myotonic dystrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
WO2007121272A2 (en) * 2006-04-11 2007-10-25 The Board Of Regents Of The University Of Texas System Methods and compositions involving nucleotide repeat disorders
US8436049B2 (en) * 2008-02-21 2013-05-07 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Uses of pentamidine and related compounds

Also Published As

Publication number Publication date
JP2013523624A (ja) 2013-06-17
CN102933224A (zh) 2013-02-13
US20130143825A1 (en) 2013-06-06
ES2365967B1 (es) 2012-09-13
CA2800248A1 (en) 2011-09-29
ES2365967A1 (es) 2011-10-14
EP2554180A4 (en) 2013-10-16
WO2011117448A1 (es) 2011-09-29
MX2012010888A (es) 2013-02-11
RU2012145458A (ru) 2014-05-10
EP2554180A1 (en) 2013-02-06

Similar Documents

Publication Publication Date Title
ES2721448T3 (es) GLYX-13 para uso en el tratamiento de enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
UY31765A (es) Dihidropirazolonas sustituidas y su uso
CU20140025A7 (es) Pirimidinas anilladas sustituidas
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
IN2012DN00624A (pt)
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
CL2012002560A1 (es) Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
ECSP10010711A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CO6382113A2 (es) Compuestos quimicos
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
EA200970816A1 (ru) Новая лекарственная форма
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
BR112012023826A2 (pt) composto para uso no tratamento de doenças baseadas na expressão de transcritos tóxicos.
ECSP088588A (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]